Literature DB >> 29373832

Nudt21 Controls Cell Fate by Connecting Alternative Polyadenylation to Chromatin Signaling.

Justin Brumbaugh, Bruno Di Stefano, Xiuye Wang, Marti Borkent, Elmira Forouzmand, Katie J Clowers, Fei Ji, Benjamin A Schwarz, Marian Kalocsay, Stephen J Elledge, Yue Chen, Ruslan I Sadreyev, Steven P Gygi, Guang Hu, Yongsheng Shi, Konrad Hochedlinger.   

Abstract

Entities:  

Year:  2018        PMID: 29373832      PMCID: PMC5831378          DOI: 10.1016/j.cell.2017.12.035

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


× No keyword cloud information.
  12 in total

1.  CFIm-mediated alternative polyadenylation remodels cellular signaling and miRNA biogenesis.

Authors:  Souvik Ghosh; Meric Ataman; Maciej Bak; Anastasiya Börsch; Alexander Schmidt; Katarzyna Buczak; Georges Martin; Beatrice Dimitriades; Christina J Herrmann; Alexander Kanitz; Mihaela Zavolan
Journal:  Nucleic Acids Res       Date:  2022-04-08       Impact factor: 16.971

2.  NUDT21 limits CD19 levels through alternative mRNA polyadenylation in B cell acute lymphoblastic leukemia.

Authors:  Matthew T Witkowski; Soobeom Lee; Eric Wang; Anna K Lee; Alexis Talbot; Chao Ma; Nikolaos Tsopoulidis; Justin Brumbaugh; Yaqi Zhao; Kathryn G Roberts; Simon J Hogg; Sofia Nomikou; Yohana E Ghebrechristos; Palaniraja Thandapani; Charles G Mullighan; Konrad Hochedlinger; Weiqiang Chen; Omar Abdel-Wahab; Justin Eyquem; Iannis Aifantis
Journal:  Nat Immunol       Date:  2022-09-22       Impact factor: 31.250

Review 3.  Context-specific regulation and function of mRNA alternative polyadenylation.

Authors:  Sibylle Mitschka; Christine Mayr
Journal:  Nat Rev Mol Cell Biol       Date:  2022-07-07       Impact factor: 113.915

4.  3' UTRs Regulate Protein Functions by Providing a Nurturing Niche during Protein Synthesis.

Authors:  Christine Mayr
Journal:  Cold Spring Harb Symp Quant Biol       Date:  2020-01-03

5.  Gain of Additional BIRC3 Protein Functions through 3'-UTR-Mediated Protein Complex Formation.

Authors:  Shih-Han Lee; Christine Mayr
Journal:  Mol Cell       Date:  2019-04-01       Impact factor: 17.970

6.  Single cell RNA-seq identifies the origins of heterogeneity in efficient cell transdifferentiation and reprogramming.

Authors:  Mirko Francesconi; Bruno Di Stefano; Clara Berenguer; Luisa de Andrés-Aguayo; Marcos Plana-Carmona; Maria Mendez-Lago; Amy Guillaumet-Adkins; Gustavo Rodriguez-Esteban; Marta Gut; Ivo G Gut; Holger Heyn; Ben Lehner; Thomas Graf
Journal:  Elife       Date:  2019-03-12       Impact factor: 8.140

7.  Partial loss of CFIm25 causes learning deficits and aberrant neuronal alternative polyadenylation.

Authors:  Callison E Alcott; Hari Krishna Yalamanchili; Ping Ji; Meike E van der Heijden; Alexander Saltzman; Nathan Elrod; Ai Lin; Mei Leng; Bhoomi Bhatt; Shuang Hao; Qi Wang; Afaf Saliba; Jianrong Tang; Anna Malovannaya; Eric J Wagner; Zhandong Liu; Huda Y Zoghbi
Journal:  Elife       Date:  2020-04-22       Impact factor: 8.140

8.  Low BACH2 Expression Predicts Adverse Outcome in Chronic Lymphocytic Leukaemia.

Authors:  Carmela Ciardullo; Katarzyna Szoltysek; Peixun Zhou; Monika Pietrowska; Lukasz Marczak; Elaine Willmore; Amir Enshaei; Anna Walaszczyk; Jia Yee Ho; Vikki Rand; Scott Marshall; Andrew G Hall; Christine J Harrison; Meera Soundararajan; Jeyanthy Eswaran
Journal:  Cancers (Basel)       Date:  2021-12-21       Impact factor: 6.639

9.  Downregulation of CFIm25 amplifies dermal fibrosis through alternative polyadenylation.

Authors:  Tingting Weng; Jingjing Huang; Eric J Wagner; Junsuk Ko; Minghua Wu; Nancy E Wareing; Yu Xiang; Ning-Yuan Chen; Ping Ji; Jose G Molina; Kelly A Volcik; Leng Han; Maureen D Mayes; Michael R Blackburn; Shervin Assassi
Journal:  J Exp Med       Date:  2020-02-03       Impact factor: 14.307

Review 10.  Stem cell programs in cancer initiation, progression, and therapy resistance.

Authors:  Tianzhi Huang; Xiao Song; Dandan Xu; Deanna Tiek; Anshika Goenka; Bingli Wu; Namratha Sastry; Bo Hu; Shi-Yuan Cheng
Journal:  Theranostics       Date:  2020-07-09       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.